Clinical trials: Inflammatory Disease
Ulcerative Colitis
Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colitis Patients with Moderate to…
- Trial name
- TOP2 (NCT02888379)
- Testing
- TOP1288
- Where
- 28 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 77 people
- Sponsor
- Topivert Pharma Ltd
Ulcerative Colitis
Open-label Extension Study of Brazikumab in Ulcerative Colitis
The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term…
- Trial name
- Expedition (NCT04277546)
- Testing
- Brazikumab Maintenance Dose, Brazikumab Induction Dose
- Where
- 36 sites in United States, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
The purpose of this trial was to investigate the safety and efficacy of mesalamine 2 g extended release granules (sachet) once a day (QD) for maintenance of clinical and endoscopic remission in subjects with UC.
- Trial name
- NCT02522780
- Testing
- Mesalamine
- Where
- 96 sites in United States, Bulgaria and 9 more
- Volunteers
- 276 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis (UC)
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.
- Trial name
- NCT05377580
- Testing
- Period 2 IBI112 dose 3, Period 1 IBI112 dose 1, Period 1 IBI112 dose 2
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Chronic Kidney Diseases, Chronic Kidney Insufficiency
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease…
- Conditions
- Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency
- Trial name
- TRANQUILITY (NCT06362759)
- Testing
- TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG
- Where
- 38 sites in United States
- Volunteers
- 143 people
- Sponsor
- Tourmaline Bio, Inc., a Novartis Company
Healthy
Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians
This study was conducted to determine safety and efficacy of topically applied cream containing combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf…
- Trial name
- NCT05986123
- Testing
- Topical cream Z for PIH
- Where
- Malaysia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- USMARI Research & Innovation Centre
Crohn's Disease
STA-5326 in Crohn's Disease Patients
The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.
- Trial name
- NCT00088062
- Testing
- STA-5326
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Synta Pharmaceuticals Corp.
Analgesia and Anti-inflammatory of Osteoarthritis
A Trial of HRF2105 Patch in Relieving Pain of Osteoarthritis
The study is being conducted to evaluate the efficacy, and safety of HRF2105patch in relieving pain of Osteoarthritis.
- Trial name
- NCT06047483
- Testing
- HRF2105 patch, Loxoprofen patch
- Volunteers
- 90 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Intestinal Disorders, Bowel Diseases, Inflammatory
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects.
- Trial name
- NCT03408470
- Testing
- TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Colitis, Ulcerative
A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia
The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with…
- Conditions
- Colitis, Ulcerative, Crohn Disease
- Trial name
- EAGLE (NCT07541261)
- Where
- Saudi Arabia
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Degenerative Osteoarthritis, Post-traumatic; Arthrosis
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
The purpose of this clinical trial is to evaluate the outcome of implanting AlloStem® graft with appropriate rigid internal fixation hardware as an alternative to autograft bone graft with rigid fixation in subtalar arthrodesis…
- Conditions
- Degenerative Osteoarthritis, Post-traumatic; Arthrosis, Rheumatoid Arthritis & Other Inflammatory Polyarthropathies, Rheumatoid Arthritis of Subtalar Joint
- Trial name
- NCT01413061
- Testing
- Subtalar Arthrodesis
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- AlloSource
Ulcerative Colitis (UC)
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157
- Trial name
- NCT03920254
- Testing
- TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C
- Where
- 184 sites in United States, Australia and 20 more
- Volunteers
- 46 people
- Sponsor
- Theravance Biopharma
Hepatitis B Infection, Congenital Malformation
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission
Immunoprophylaxis with two hepatitis B vaccinations following the hepatitis B immune globulin (HBIg) and hepatitis B vaccine at birth is largely effective in protecting infants from hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia
- Trial name
- NCT03476083
- Testing
- Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
- Where
- 7 sites in China
- Volunteers
- 280 people
- Sponsor
- New Discovery LLC
Colitis, Ulcerative
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of BI 655130…
- Trial name
- NCT03648541
- Testing
- Spesolimab
- Where
- 38 sites in United States, Austria and 10 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease
A double-blind, multicentre, stratified by centre, randomised, parallel study with two groups of adult patients operated on for Crohn's disease, to determine if oral ingestion of probiotics could prevent the appearance of Crohn's…
- Trial name
- NCT01698970
- Testing
- 1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test), 2- excipients (150 mg) in capsule (control)
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Danone Global Research & Innovation Center
Ulcerative Colitis, Crohn's Disease
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
- Trial name
- NCT01290042
- Testing
- AMG 181
- Where
- 8 sites in United States, Australia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Amgen
Respiratory Tract Infections, Urinary Tract Infections
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- SEPSIS-SHIELD (NCT04094818)
- Testing
- TriVerity
- Where
- 26 sites in United States, Greece
- Volunteers
- 1,441 people
- Sponsor
- Inflammatix
Breast Cancer Metastatic
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human…
- Trial name
- NCT04215146
- Testing
- Paclitaxel, Pelareorep, Avelumab
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oncolytics Biotech
Multiple Sclerosis
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks.
- Trial name
- AFFINITY (NCT03222973)
- Testing
- BIIB033 (opicinumab)
- Where
- 159 sites in United States, Australia and 13 more
- Volunteers
- 263 people
- Sponsor
- Biogen
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.